Sarepta says ELEVIDYS shows 2-year functional gains in 8-12-year-old Duchenne patients versus external controls at WMS 2026
SRPT•Sarepta said two-year follow-up showed sustained functional performance in boys treated with ELEVIDYS at ages 8-12 versus matched external controls, with no new safety signals reported.
1. Two-year follow-up
Sarepta presented data at the 2026 World Muscle Society annual congress showing sustained functional performance in boys treated with ELEVIDYS at ages 8-12 versus a matched external control, suggesting slower disease progression. The company said safety remained consistent with the established profile, with no new safety signals reported across the analyses.
